According to sources, Novo Holdings plans to invest $16.5 billion in acquiring Catalent. The European Union antitrust regulatory agency has requested pharmaceutical industry competitors and customers to provide feedback on four business areas. Novo Holdings, the controlling shareholder of Danish pharmaceutical company Novo Nordisk, has become Europe's highest market cap company driven by the lucrative profits from the popular weight loss drug Wegovy. Although the survey shows that the European Commission is seeking to understand the market, it may allow competitors and customers to raise potential antitrust issues. The EU regulatory agency has set December 6 as the deadline for the preliminary review. If necessary, Novo Holdings must submit remedies by November 29. This $16.5 billion deal highlights Novo Nordisk's efforts to increase Wegovy production. Both companies have recently reiterated their expectations that the transaction will be completed by the end of this year.